In 2007, fusion proteins belonged to the top four most lucrative biotech drugs. Featuring contributions from leaders in the field, Fusion Protein Technologies for Biopharmaceuticals presents the state-of-the-art for development of fusion proteins, demonstrates current concepts, describes multiple applications, and discusses typical challenges linked to these molecules. The book combines the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs addressing unmet medical needs. Comparing proven and emerging fusion protein technologies, the text explores the major types of therapeutic fusion proteins, including antibody, multifunctional, cell killing, and T-cell inhibitors.